

BEST AVAILABLE COPY

VIA HAND DELIVERY DECEMBER 19, 2001

#33/YR

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

05-08-02

Application of: Hastings et al.

Attorney Docket No.: PF147D1

Application Serial No.: 09/037,460

Art Unit: 1647

Filed. March 10, 1998

Examiner: Saoud, C.

Title: Human Vascular IBP-Like Growth Factor
Polynucleotides (as amended)**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**
PURSUANT TO 37 CFR 1.97Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to references A1-AJ listed on the attached Form PTO/SB/08. A copy of each reference is enclosed.

The listed references are presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 C.F.R. § 1.104(a) concerning the Examiner's duty to consider and use any such information. Applicants respectfully request that the Examiner make the listed references of record in the file history of the application, and consider the information contained therein during the prosecution of this application.


Identification of the listed references is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to take appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Pursuant to 37 C.F.R. § 1.97(c), since this Supplemental Information Disclosure Statement is being filed after the mailing date of a first Office Action on the merits and before either a final action under 37 C.F.R. § 1.113, a Notice of Allowance under 37 C.F.R. § 1.311, or an action that otherwise closes prosecution, the Patent and Trademark Office will consider this Supplemental Information Disclosure Statement if it is accompanied either by a statement as specified in 37 C.F.R. § 1.97(e) or the fee as specified in 37 C.F.R. § 1.17(p).

Accordingly, the Patent Office is hereby authorized to charge our Deposit Account No. 08-3425 in the amount of \$180.00 as payment of the fee required under 37 CFR § 1.17(p). The Patent Office is also authorized to charge any additional required fee or credit any overpayment in connection with this submission to our Deposit Account No. 08-3425.

Respectfully submitted,

Dated: December 19, 2001


Jonathan L. Klein (Reg. No. 41,119)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
(301) 251-6015 (phone)

JLK/CCB/ba